Skip to content

Hyperbaric oxygen therapy for cognitive dysfunction induced by nitrous oxide abuse: an intervention-controlled study

Hyperbaric oxygen therapy for cognitive dysfunction induced by nitrous oxide abuse: an intervention-controlled study

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043533
Enrollment
Unknown
Registered
2021-02-21
Start date
2021-03-01
Completion date
Unknown
Last updated
2021-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cognitive function induced by nitrous oxide

Interventions

Sponsors

Mental Health Center of West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with a clear history of N2O exposure, meeting the diagnostic criteria for substance abuse in DSM-5, 2. Who presents acute, subacute or chronic symptoms of cognitive decline, such as memory decline, disorientation, attention deficit, slower reaction, and learning disability will be eligible for inclusion. 3. Volunteer to participate in this study and sign informed consent.

Exclusion criteria

Exclusion criteria: Patients with organic brain diseases (eg, intracerebral hemorrhage, cerebral infarction), psychoactive substance abuse (in addition to alcohol, tobacco and caffeine), contraindications to hyperbaric oxygen therapy, other causes of cognitive decline.

Design outcomes

Primary

MeasureTime frame
processing speed;attention;working memory;verbal learning;visual learning;reasoning and problem solving;social cognition;Visual Continuous Attention Test;Auditory Continuous Attention Test;The Wisconsin Card Sorting Test;Raven's Standard Progressive Matrices;Stroop Colour Word Interference test;

Contacts

Public ContactXu Jiajun

West China Hospital of Sichuan University

xujiajun120@126.com+86 17381883373

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026